Ataxia Market Report 2026

The ataxia market size has grown strongly in recent years. It will grow from $40.45 billion in 2025 to $43.95 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to improved neurological disorder recognition, expansion of diagnostic imaging availability, increased research into rare neurological diseases, growing clinical awareness of ataxia subtypes, availability of supportive care options.

The ataxia market size is expected to see strong growth in the next few years. It will grow to $61.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing investments in gene-based therapies, rising adoption of personalized neurology treatments, expansion of digital monitoring for neurological conditions, growing focus on rare disease drug development, increasing collaboration in neurological research. Major trends in the forecast period include increasing focus on genetic testing and counseling, rising adoption of symptomatic treatment approaches, growing use of advanced neurodiagnostic tools, expansion of long-term disease management strategies, enhanced emphasis on early diagnosis.

The increase in alcohol consumption is expected to drive the growth of the ataxia market in the coming years. Alcohol consumption refers to the intake of beverages containing ethanol, typically by mouth. Cerebellar degeneration, a common type of acquired toxic ataxia, is caused by prolonged alcohol misuse. Individuals with alcoholism often exhibit lower limb postural tremors and gait ataxia. For example, in August 2024, according to GOV.UK, a UK-based government department, the provisional total for alcohol duty receipts from wine and other fermented products between May and July 2024 was $1.52 billion (£1,154 million), representing an increase of $42 million (£32 million) (2.9%) compared to the same period the previous year. Consequently, the rise in alcohol consumption is contributing to the growth of the ataxia market.

Major companies in the ataxia market are concentrating on creating innovative solutions, such as first-in-class oral drug therapies, to address the growing need for effective treatments that can slow disease progression and enhance functional outcomes in rare neurodegenerative disorders. These oral therapies provide a convenient, non-invasive alternative to conventional supportive care methods that mainly focus on symptom management without targeting underlying disease mechanisms. For example, in February 2023, Reata Pharmaceuticals, a US-based biotechnology firm, announced FDA (U.S. Food and Drug Administration) approval of SKYCLARYS (omavaloxolone). It is the first and only medication approved for treating Friedreich's ataxia in adults and adolescents aged 16 and older. By Week 48, treatment with the once-daily oral drug SKYCLARYS resulted in statistically significant lower mFARS (modified Friedreich's Ataxia Rating Scale) scores, indicating reduced impairment, compared to placebo. Friedreich's ataxia, a very rare inherited neurological disorder, is typically diagnosed around adolescence.

In September 2023, Biogen, a US-based biopharmaceutical company, acquired Reata Pharmaceuticals for $7.3 billion. Through this acquisition, Biogen intends to strengthen its position in the ataxia market by incorporating Reata’s lead therapy, SKYCLARYS® (omaveloxolone), and utilizing its pipeline of therapeutics focused on neurodegenerative and mitochondrial disorders. Reata Pharmaceuticals is a US-based biopharmaceutical company that develops innovative small-molecule therapeutics, including the first FDA-approved treatment for Friedreich’s ataxia.

Major companies operating in the ataxia market are Pfizer Inc., Johnson & Johnson Services Inc., Eisai Co. Ltd., Genentech Inc., CRISPR Therapeutics AG, Eli Lilly & Company, GlaxoSmithKline Plc, Larimar Therapeutics Inc., Capsida Biotherapeutics Inc., Intellia Therapeutics Inc., Bluebird bio Inc., Editas Medicine Inc., Healx, Acorda Therapeutics Inc., H. Lundbeck A/S, Reata Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals Inc., IntraBio, Biogen Inc., Novartis AG, Sanofi, Roche Holding Ltd., Teva Pharmaceuticals, Zydus Lifesciences Ltd.

North America was the largest region in the ataxia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the ataxia market report during the forecast period. The regions covered in the ataxia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ataxia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the ataxia market by increasing costs of imported diagnostic imaging equipment, genetic testing kits, laboratory instruments, and pharmaceutical raw materials used in treatment and diagnosis. Healthcare providers in North America and Europe are most affected due to reliance on imported medical technologies, while Asia-Pacific faces cost pressure on drug manufacturing inputs. These tariffs are increasing diagnostic and treatment costs for patients. However, they are also encouraging domestic production of diagnostic tools, regional pharmaceutical manufacturing, and localized research initiatives for neurological disorder management.

The ataxia market research report is one of a series of new reports that provides ataxia market statistics, including ataxia industry global market size, regional shares, competitors with a ataxia market share, detailed ataxia market segments, market trends and opportunities, and any further data you may need to thrive in the ataxia industry. This ataxia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ataxia is a neurological condition that leads to unsteady movements and balance problems due to a loss of muscle control and coordination. It affects the limbs, speech, and eye movements, as well as other parts of the body.

The primary types of ataxias include Friedreich's ataxia, ataxia-telangiectasia, episodic ataxia, and others. Friedreich's ataxia is a rare genetic disorder that affects movement and progressively damages the nervous system. It can be managed with various products, including treatments and diagnostic options. The different types of dosage forms include solids, liquids, and others, which can be delivered through multiple routes, such as oral, parenteral, and others. It is utilized by various end-users, including hospitals, clinics, home healthcare, and others.

The ataxia market consists of revenues earned by entities by providing serotonergic therapy, occupational therapy, vestibular rehabilitation, and hyperbaric oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The ataxia market also includes sales of adaptive devices including walkers or canes, acetazolamide, and amantadine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.